Slide 1: Investor Presentation September 2020
Jubilant Life Sciences Limited Investor Presentation September 2020
Slide 2: Disclaimer
Disclaimer Important Disclaimer This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Life Sciences Limited (the “Company”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for
Slide 3: Jubilant Life Sciences Overview
Jubilant Life Sciences Overview Pharmaceuticals Life Science Ingredients DDDS1 Specialty Pharmaceuticals Specialty Intermediates Radiopharma Advanced Intermediates Drug Discovery Allergy Therapy Products Specialty Ingredients Services (Jubilant Biosys) CDMO Nutritional Products CMO of Ster
Slide 4: Pharmaceuticals Segment
f) we - . i a wW jupiaAnt Pharmaceuticals Segment LIFESCIENCES
Slide 5: Evolution of Jubilant Pharma
Evolution of Jubilant Pharma Revenue Contribution JLL acquired Acquired a majority stake Acquired Draxis Pharma SGX-listed high Completed FY20 API business – in Cadista Holdings Inc. Inc. in Canada yield bond acquisition of US$803m Nanjangud, (generics pharmaceutical (manufacturer of sterile offerin
Slide 6: Radiopharmaceuticals Business
Radiopharmaceuticals Business Radiopharmaceuticals Industry in North America is US$2.4bn Market Size of Industry in North America Expected to grow at CAGR of 6.2% to reach US$3.5bn by 2023 3.5 3.0 3.2 Industry 2.7 2.9 Oncology and cardiology diagnosis accounted for 69.4% of the industry in 201
Slide 7: Radiopharmaceuticals Business – Key Products
Radiopharmaceuticals Business – Key Products RUBY-FILL® (Rubidium Kit for the Preparation HICON® Sodium Iodide Rb-82 Generator) and of Technetium Tc 99m I-131 Solution USP Elution System Albumin Aggregated Injection (MAA) The RUBY-FILL® Rubidium Rb 82 Used as an adjunct in the evaluation of HI
Slide 8: Radiopharmacy Business
Radiopharmacy Business # 2 commercial radiopharmacy network(1) in the US, operated under the Jubilant Radiopharmacy brand Facilities include three cyclotrons Multi-year agreements with GPOs in place 49 radiopharmacies spread across 22 states ~750 employees c.2.8 mn+ doses delivered annually c.
Slide 9: Allergy Therapy Business
Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size Global AIT market stands at US$1.6bn and is expected to grow at CAGR of 8.9% to reach 2.8 2.6 US$2.8bn by 2022 2.3 0.5 2.0 2.1 1.8 0.4 1.6 1.7 0.4 Major growth drivers include the increased prevalence of allergic diseases, reduced
Slide 10: Allergy Therapy Business – Key Products
Allergy Therapy Business – Key Products ComforTen Skin Test System QUINTIP® Skin Test Device Venom products The only self-loading, surgical steel skin test system on the market More than 16 million Americans are at risk for a Surgical steel 1.2 mm lancet tips are uniquely designed for minimal
Slide 11: Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products
Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products Global Pharmaceutical CMO Industry Size 125 134 100 109 117 5 5 7 Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a 79 85 92 4 5 6 5 6 12 11 7 12 73 4 6 11 Industry 59
Slide 12: API Business
API Business Global Market Size : Synthetic API1 149 123 131 129 Global Synthetic API market is US$115bn in 2018 and is expected to grow at a 115 Industry 53 46 62 CAGR of 6.7% from 2018 to 2022F to reach US$149bn(1) 51 (US$bn) 48 Overview 53% of outsourced API market is generics(1) 67 72 78 83
Slide 13: Solid Dosage Formulations Business
Solid Dosage Formulations Business Global Generics Pharmaceuticals Industry Size by Unbranded Generic US Patent Expiry for Small Molecules Sales(1)(3) Global generics pharmaceutical industry stands at US$111bn and is expected to grow at CAGR of 5.2% to reach US$136bn US$ 72.5 bn 136 by 2023 117 12
Slide 14: Life Science Ingredients Segment
Life Science Ingredients Segment
Slide 15: Specialty Intermediates
Specialty Intermediates Global Market Size ($ Bn) : Speciality Chemicals Global specialty chemicals market is USD 240 billion in 2019 and is expected to grow at 5.4% to reach USD 267 billion in 2022. Industry New Opportunities in Pharma and Agro chemicals are emerging Overview post Covid pandemi
Slide 16: Nutritional Products
Nutritional Products Global nutrition market is USD 570 billion in 2019 , largely dominated by feed business and food ingredients. Industry Animal Feed contributes ~80% of total Nutrition market Overview Animal Feed Additive market in India is valued at Rs. 3,600 Cr. growing at 4.6% CAGR Sourc
Slide 17: Life Science Chemicals
Life Science Chemicals Global Market Size (KT): Acetic Global Market Size (KT): Ethyl Anhydride Acetate Global Acetic Anhydride market is 589 KT in FY’20 and is expected to Industry grow at 2.2% to reach 657KT in FY’25 Overview Global Ethyl Acetate market is 2150 KT in FY’20 and is expected to g
Slide 18: Drug Discovery & Development Solutions (Jubilant Biosys)
Drug Discovery & Development Solutions (Jubilant Biosys)
Slide 19: Drug Discovery & Development Solutions
Drug Discovery & Development Solutions Overview Discovery Services up to IND & GMP Drug Discovery Services (Drug Discovery Services) business through Jubilant Biosys Limited provides innovation and collaborative research Full suite of services to our customers including through two research center
Slide 20: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics)
Slide 21: Proprietary Drug Discovery
Proprietary Drug Discovery Innovative Biotech funded and launched as a standalone On value inflection path from preclinical stage to clinical stage US-based entity in 2019 by parent- a global life sciences –two lead programs expected to transition to clinic in 12-18 company months: • Risk diversifie
Slide 22: Proprietary Drug Discovery
Proprietary Drug Discovery Agile and flexible business model to accelerate value creation EXTERNAL VALUE FUNDING UNLOCKING VC / PE Corporate Funding IPO / M&A Strategic investor Parent Company 25-50 Dedicated Scientists PORTFOLIO IN-LICENSING/ OF ASSETS IN OUT-LICENSING/ PARTNERING SUBSIDIARIES PART
Slide 23: Jubilant Life Sciences – Key Strengths & Strategies
Jubilant Life Sciences – Key Strengths & Strategies
Slide 24: Jubilant Life Sciences Key Strengths
Jubilant Life Sciences Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De-risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High-Quality, World –Class, Lo
Slide 25: Leading Market Positions Across Business Lines, with High Barriers to Entry
Leading Market Positions Across Business Lines, with High Barriers To 1 Entry For Specialty Pharmaceuticals Highlights Entry Barriers #3 radiopharmaceuticals manufacturer in the US (1) Extensive regulatory and licensing requirements #2 commercial radiopharmacy network in the US (1) Specialty P
Slide 26: Global Competitive Edge Due to Low Cost and Vertical Integration
Global Competitive Edge Due to Low Cost and Vertical 2 Integration Vertical integration across the value chain enables cost competitive advantage resulting in higher margins Integrated Operations… Life Sciences Ingredients Animal & Speciality Radiopharmacies Ingredients Vitamins Human Provides dir
Slide 27: De-risked Business Model With Diverse Sources of Revenue
3 De-risked Business Model With Diverse Sources of Revenue Presence in niche Specialty businesses that have high barriers to entry Diverse end-use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries Presence across geographic locations ena
Slide 28: Strong Pipeline of Products With Deep R&D Capabilities
4 Strong Pipeline of Products With Deep R&D Capabilities Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma Strong R&D support with a dedicated workforce of ~500 R&D professionals. 919 patents filed till FY20 Strong pipeline of 8 produc
Slide 29: High-Quality, World-Class, Low Cost Manufacturing Footprint
5 High-Quality, World-Class, Low Cost Manufacturing Footprint Spokane, Washington, USA Roorkee, Uttarakhand Contract manufacturing of Sterile Generics manufacturing injectable and Allergy therapy Gajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and Samlaya, Gujara
Slide 30: Experienced Management Team with High Standards of Corporate Governance
Experienced Management team with high standards of corporate 6 governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 39 industry years in pharma, specialty 33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foods, oil and ga
Slide 31: Demonstrated Financial Track Record with Strong Revenue Growth
Demonstrated Financial Track Record with Strong Revenue Growth and 7 Attractive Profitability Profile Revenue from Operations1 Total Revenue EBITDA Split1 Reported EBITDA2 Revenue increased at a CAGR of 9.5% over FY15-20 and EBITDA 5,826 5,893 5,861 7,518 9,111 9,154 732 1,291 1,370 1,558 1,775 1,
Slide 32: Growth Strategies and Plans
Growth Strategies and Plans 1 Continue to strengthen leadership positions in key business segments Radiopharma: Achieve market leadership by leveraging leadership in existing products and broad distribution network along with expansion of our product portfolio through launch of niche and different
Slide 33: Growth Strategies and Plans
Growth Strategies and Plans 3 Develop a diverse product and service portfolio through differentiated and complex offerings Specialty Pharmaceuticals Focus: Develop differentiated products in the radiopharmaceuticals and specialty injectables segments catering to the North American market CDMO Fo
Slide 34: Q1'FY21 Results Analysis
Q1’FY21 Results Analysis Ww JUBUANT ‘LIFESCIENCES
Slide 35: JLL – Q1'FY21 Financial Highlights
JLL – Q1’FY21 Financial Highlights 1 YoY Particulars Q1'FY20 Q1'FY21 Change (%) Revenue Revenue at Rs 1,893 Crore, as compared with Rs 2,182 Crore in Q1’FY20 Pharmaceuticals2 1,328 1,096 (18%) • Pharmaceuticals revenue at Rs 1,096 Crore as compared to Rs 1,328 Life Science Ingredients 805 737 (9%)
Slide 36: Debt Profile Q1'FY21
Debt Profile Q1’FY21 Particulars 31/03/20 30/06/20 Foreign Currency Loans ($ Mn) ($ Mn) Subsidiaries 431 435 Total 431 435 Net Debt (constant Rupee Loans (Rs. Crs) (Rs. Crs) currency) reduction of Rs Standalone 1,295 985 343 Crore in Q1’FY21 as Subsidiaries 100 160 compared to March 31, Total 1,39
Slide 37: Income Statement – Q1'FY21
Income Statement – Q1’FY21 Particulars1 Q1'FY20 Q1'FY21 YoY Growth Total Revenue from Operations 2,182 1,893 (13%) Pharmaceuticals 1,328 1,096 (18%) Life Science Ingredients 805 737 (9%) Drug Discovery & Development Solutions 48 60 26% Total Expenditure 1,747 1,602 (8%) Other Income 10 7 Segment EBI
Slide 38: FY20 Results Analysis
FY20 Results Analysis Ww JUBUANT ‘LIFESCIENCES
Slide 39: JLL – FY20 Financial Highlights
JLL – FY20 Financial Highlights YoY 1 Particulars FY19 FY20 Change (%) Revenue at Rs 9,154 Crore up from Rs 9,111 Crore in FY19 Revenue • Pharmaceuticals revenue at Rs 5,714 Crore, increased by 7% YoY, Pharmaceuticals 2 5,349 5,714 7% contributing 62% to revenue Life Science Ingredients 3,545 3,17
Slide 40: Adjusted Earnings
Adjusted Earnings Rs Crore Consol EBITDA % Change % Change S. No. Particulars Q4'FY19 Q4'FY20 YoY FY19 FY20 YoY 1 Reported EBITDA 351 556 58% 1,775 1,995 12% 2 One-off Adjustments 37 12 85 72 3 Adjusted EBITDA 388 568 46% 1,860 2,066 11% 4 Reported EBITDA Margin 14.7% 23.3% 19.5% 21.8% 5 Adjusted EB
Slide 41: Income Statement – Q4 & 12M'FY20
Income Statement – Q4 & 12M’FY20 Particulars1 Q4'FY19 Q4'FY20 YoY Growth FY19 FY20 YoY Growth Total Revenue from Operations 2,386 2,391 0% 9111 9,154 0% Pharmaceuticals 1,405 1,483 6% 5349 5,714 7% Life Science Ingredients 912 823 (10%) 3545 3,179 (10%) Drug Discovery & Development Solutions 68 85 2
Slide 42: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019 the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certain P
Slide 43: For more information
For more information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002| 21 Ph: +91 22 6645 1209 E-mail: hemant.bakhru@jubl.com E-mail: siddharth@cdr-india.com pavleen.taneja@jubl.com For Media: Sudhakar Safaya Clayton Dsou